C - Chemistry – Metallurgy – 07 – H
Patent
C - Chemistry, Metallurgy
07
H
C07H 19/10 (2006.01) A61K 31/7068 (2006.01) A61K 31/7072 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2518115
Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an .alpha.-amino acid moiety. The .alpha.-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.
L'invention concerne des dérivés de phosphoramidate de nucléotides, ainsi que leur utilisation dans le traitement du cancer. Les fractions de base de désoxyuridine, de cytarabine, de gemcitabine et de cytidine, par exemple, peuvent être substituées en position 5. La fraction de phosphoramidate comporte une fraction aryl-O et une fraction .alpha.-acide aminé fixées sur l'atome P. La fraction .alpha.-acide aminé peut correspondre à un acide aminé d'origine naturelle ou à un acide aminé d'origine non naturelle, ou être issue de celui-ci.
Cardiff Protides Limited
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
University College Cardiff Consultants Limited
LandOfFree
Nucleotide phosphoramidates as anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleotide phosphoramidates as anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide phosphoramidates as anticancer agents will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1624142